-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath
Drug Evaluation: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation
-
Drug-eluting balloons: where are we and what are the problems?
Beatrix Schnorr, Ulrich Speck, Bruno Scheller
Editorial: Clinical Investigation